| Name | Title | Contact Details |
|---|
Caribbean Clinical Research ASsociates is a East Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ServRx is a leading national workers` compensation prescription drug claims processing company. With a strong backbone of proprietary IT and decades of experience in the workers` compensation space, ServRx serves a rapidly growing share of community and independent pharmacies. Across America, each pharmacy client is as unique as the injured workers they treat. ServRx prides itself on creating customized solutions to meet the needs of our diverse client-base. Rural mom-and-pop pharmacies, regional chains, specialty pharmacies, and large pharmacy management firms alike have turned to ServRx to handle the unique workflow and cash-flow challenges posed by workers` compensation. A winning mix of experience, technology, and economies of scale allows ServRx to promise its clients superior handling of their workers` compensation claims. Whether they process one pharmacy claim per week, or hundreds per day, ServRx clients have something in common: peace of mind and increased profitability.
REM Associates is a Bonsall, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
POZEN Inc. is a specialty pharmaceutical company that to date has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.
Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera`s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus.